OmniAb Inc. Surpasses Expectations in Q3 2026, Announces Groundbreaking Partnerships
OmniAb Inc., a leading biotech company specializing in next-generation therapeutics discovery, has made significant strides in the third quarter of 2026. The company's recent conference call highlighted impressive achievements, including a major licensing deal with Eli Lilly and strong performance across various programs.
During the conference call, Matt Foehr, President and CEO of OmniAb Inc., presented highlights from the quarter, underscoring the company's ability to drive growth through diversified revenue streams. "Our highly differentiated technology platforms are facilitating growth in partnerships and progression of programs," he stated. The announcement of a major new deal with Eli Lilly for a novel ion channel program marked a significant milestone for OmniAb Inc., solidifying its position as a key enabling technology licensing partner.
The terms of the license agreement are equally impressive, with OmniAb Inc. receiving an upfront payment and eligible to receive up to $370 million in research, development, and commercial milestone payments, as well as potential tiered royalties on global net sales. This partnership not only showcases the company's expertise but also demonstrates its commitment to addressing major unmet medical needs.
In addition to the licensing deal with Eli Lilly, OmniAb Inc. has been actively engaged in driving strong performance across various programs, seeing increased utilization of its differentiated technologies within a growing ecosystem of partners. The company's xPloration platform, an AI-powered high-throughput single B-cell screening platform, is now available to all potential customers, creating valuable opportunities for business growth.
OmniAb Inc. has also launched OmniTides, a new peptide discovery offering powered by its OmniUltra transgenic chicken. This integrated discovery-to-synthesis workflow provides partners with an optimized peptides solution for various growing therapeutic applications. The company's continued strong business performance has resulted in yet another raise to its 2026 revenue and cash outlook.
As highlighted during the conference call, OmniAb Inc.'s novel technologies reinforce its position as a key enabling technology licensing partner and support both existing and new partnerships. The company's capabilities, combined with its vantage point in the industry, keep it at the forefront of next-generation therapeutics discovery, positioning it to create meaningful value for its stakeholders.
